Last reviewed · How we verify
Monotherapy Etoricoxib
Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation.
Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.
At a glance
| Generic name | Monotherapy Etoricoxib |
|---|---|
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Etoricoxib is a selective COX-2 inhibitor that preferentially blocks the COX-2 enzyme over COX-1, thereby reducing the synthesis of pro-inflammatory prostaglandins while sparing the protective effects of COX-1-derived prostaglandins in the gastrointestinal tract and kidneys. This selective inhibition provides anti-inflammatory, analgesic, and antipyretic effects with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute pain
- Ankylosing spondylitis
Common side effects
- Hypertension
- Edema
- Dyspepsia
- Abdominal pain
- Diarrhea
- Headache
Key clinical trials
- Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis (PHASE3)
- Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |